Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

Company Overview

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

Key Stats

• Today's Range: $15.25 to $15.25
• 50-Day Range: $15.18 to $15.25
• 52-Week Range: $4.81 to $15.37
• Volume: 600 shs
• Average Volume: 974,748 shs
• Market Capitalization: $753.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Aerie Pharmaceuticals Stock Analysis - MarketRank™

Aerie Pharmaceuticals scored higher than 9% of companies evaluated by MarketBeat, and ranked 975th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Aerie Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($2.02) to ($1.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aerie Pharmaceuticals is -19.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AERI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aerie Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Aerie Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -2.53

Short Interest

There is no current short interest data available for AERI.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aerie Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aerie Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.44% of the stock of Aerie Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Aerie Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AERI Stock Analysis - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The company had revenue of $29.31 million for the quarter, compared to analyst estimates of $29.13 million.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD) and Puma Biotechnology (PBYI).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 10/02/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AERI
• CUSIP: N/A
• CIK: 1337553
• Web: www.aeriepharma.com
• Phone: (919) 237-5300
• Fax: 949-526-8787
• Employees: 376
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-74,810,000.00
• Net Margins: -17.09%
• Pretax Margin: -16.47%
• Return on Equity: N/A
• Return on Assets: -2.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.27
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: $194.13 million
• Price / Sales: 3.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.32) per share
• Price / Book: -4.59

Miscellaneous

• Outstanding Shares: 49,417,000
• Free Float: 47,223,000
• Market Cap: $753.61 million
• Optionable: Optionable
• Beta: -0.06